NasdaqGM:AXSMPharmaceuticals
Faster Revenue Growth With Wider Losses Might Change The Case For Investing In Axsome (AXSM)
Axsome Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue rising to US$218.38 million from US$150.04 million a year earlier, while net loss widened to US$51.31 million and basic loss per share from continuing operations was US$0.99.
Despite strong year-over-year revenue growth across both the quarter and first half of 2026, Axsome’s net losses and loss per share both increased, underscoring the cost of its expanding CNS portfolio and commercialization efforts.
We...